Clinical Trial Update: Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for masitinib in patients with mastocytosis carrying the D816V mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mastocytosis

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Mastocytosis | Phase 2 | Status: COMPLETED